Mostra 1 - 4 risultati di 4 ricerca 'Evan Y Yu', tempo di risposta: 0,03s Raffina i risultati
  1. 1
    Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report

    Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate ca... di Michael Lai, Evan Y Yu, Michael T Schweizer, Darien E Reed-Perino

    Pubblicazione 2023-05-01
    Testo
    Articolo
  2. 2
    Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

    Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer di Franklin C. Lee, William Harris, Heather H. Cheng, Jaideep Shenoi, Song Zhao, Junfeng Wang, Thomas Champion, Jason Izard, John L. Gore, Michael Porter, Evan Y. Yu, Jonathan L. Wright

    Pubblicazione 2013-01-01
    Testo
    Articolo
  3. 3
    Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates

    Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates di Azra Ajkunic, Erolcan Sayar, Martine P. Roudier, Radhika A. Patel, Ilsa M. Coleman, Navonil De Sarkar, Brian Hanratty, Mohamed Adil, Jimmy Zhao, Samir Zaidi, Lawrence D. True, Jamie M. Sperger, Heather H. Cheng, Evan Y. Yu, Robert B. Montgomery, Jessica E. Hawley, Gavin Ha, Thomas Persse, Patricia Galipeau, John K. Lee, Stephanie A. Harmon, Eva Corey, Joshua M. Lang, Charles L. Sawyers, Colm Morrissey, Michael T. Schweizer, Roman Gulati, Peter S. Nelson, Michael C. Haffner

    Pubblicazione 2024-05-01
    Testo
    Articolo
  4. 4
    Perioperative Blood Transfusion Is Associated with Worse Survival in Patients Undergoing Radical Cystectomy after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

    Perioperative Blood Transfusion Is Associated with Worse Survival in Patients Undergoing Radical Cystectomy after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer di Tessa Ladner, Anna J. Black, Homayoun Zargar, Jonathan L. Wright, Andrew C. Thorpe, Todd M. Morgan, Jeff M. Holzbeierlein, Michael S. Cookson, Niels-Erik Jacobsen, Adrian S. Fairey, Colin P. N. Dinney, Maria C. Mir, Laura-Maria Krabbe, Jeffrey S. Montgomery, Nikhil Vasdev, Evan Y. Yu, Evanguelos Xylinas, Andrew J. Stephenson, Jay B. Shah, Siamak Daneshmand, Kamran Zargar-Shoshtari, Philippe E. Spiess, Laura S. Mertens, Bas W. G. van Rhijn, Petros Grivas, Wassim Kassouf, Marc A. Dall’Era, Srikala S. Sridhar, Jonathan S. McGrath, Jonathan Aning, Shahrokh F. Shariat, Trinity J. Bivalacqua, Scott A. North, Daniel A. Barocas, Yair Lotan, Peter C. Black

    Pubblicazione 2024-06-01
    Testo
    Articolo

Strumenti per la ricerca: